Alzheimer’s jab failed to meet goal on reducing memory decline, company says

Roche has announced disappointing results from drug trials (PA)

A new jab for people with early-stage Alzheimer’s has failed to show it can slow down a decline in memory and thinking, according to pharmaceutical giant Roche.

The drug, gantenerumab, is an antibody medicine that held much promise as it entered phase three clinical trials.